Carreno_2026_belantamab_kva <- function() {
  description <- paste(
    "Continuous-time Markov model (CTMM) of ophthalmic exam finding grades",
    "on the Keratopathy and Visual Acuity (KVA) scale (grades 0, 1, 2 and",
    "3/4 combined) in adults with relapsed/refractory multiple myeloma",
    "treated with belantamab mafodotin as monotherapy or with bortezomib,",
    "lenalidomide or pomalidomide plus dexamethasone (Carreno 2026).",
    "Upward transitions are driven by a power function of the central",
    "belantamab mafodotin concentration, downward transitions occur without",
    "drug and slow as concentration rises; baseline sBCMA and the",
    "combination backbone modify the rates. The belantamab mafodotin PK",
    "driver is the Papathanasiou 2025 two-compartment",
    "time-varying-clearance covariate model with the values printed in the",
    "Carreno 2026 mrgsolve code (File S2).",
    sep = " "
  )
  reference <- paste(
    "Carreno F, van Noort M, Taylor A, Zeiser S, Papathanasiou T, Post TM,",
    "Lien YT(K), Ho YL, Ferron-Brady G. Simulation Framework to Investigate",
    "Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in",
    "Relapsed/Refractory Multiple Myeloma. CPT Pharmacometrics Syst",
    "Pharmacol. 2026;15(6):e70276. doi:10.1002/psp4.70276.",
    "PK driver: Papathanasiou T et al. Clin Pharmacokinet.",
    "2025;64(6):925-942. doi:10.1007/s40262-025-01508-1.",
    sep = " "
  )
  vignette <- "Carreno_2026_belantamab"
  units <- list(time = "day", dosing = "mg", concentration = "ug/mL")

  # Markov state-occupancy probabilities of the four KVA grade states; the
  # KVA scale is specific to belantamab mafodotin ocular findings.
  paper_specific_compartments <- c("s_kva0", "s_kva1", "s_kva2", "s_kva34")

  compartmentData <- list(
    central = list(analyte = "belantamab mafodotin", units = "mg", specimen = "plasma", verified = TRUE),
    peripheral1 = list(analyte = "belantamab mafodotin", units = "mg", specimen = "plasma", verified = TRUE),
    s_kva0 = list(
      analyte = "probability of KVA grade 0",
      units = NA_character_,
      specimen = "not applicable",
      verified = TRUE
    ),
    s_kva1 = list(
      analyte = "probability of KVA grade 1",
      units = NA_character_,
      specimen = "not applicable",
      verified = TRUE
    ),
    s_kva2 = list(
      analyte = "probability of KVA grade 2",
      units = NA_character_,
      specimen = "not applicable",
      verified = TRUE
    ),
    s_kva34 = list(
      analyte = "probability of KVA grade 3 or 4",
      units = NA_character_,
      specimen = "not applicable",
      verified = TRUE
    )
  )

  covariateData <- list(
    IGG = list(
      description = "Baseline serum immunoglobulin G concentration",
      units = "g/L",
      type = "continuous",
      reference_category = NULL,
      notes = "PK driver only. Power exponents on CL (0.170) and Imax (0.192) with reference 15 g/L (File S2 THETA13, THETA119).",
      source_name = "IGGBL"
    ),
    WT = list(
      description = "Baseline body weight",
      units = "kg",
      type = "continuous",
      reference_category = NULL,
      notes = "PK driver. Power exponent 0.929 on V1 and V2 and 0.542 on CL and Q; reference 75 kg (File S2 THETA8, THETA9).",
      source_name = "WTBL"
    ),
    ALB = list(
      description = "Baseline serum albumin concentration",
      units = "g/L",
      type = "continuous",
      reference_category = NULL,
      notes = "PK driver. Power exponents -0.698 on CL, -0.302 on V1 and +0.567 on V2; reference 40 g/L (File S2 THETA10, THETA11, THETA121).",
      source_name = "ALBBL"
    ),
    SBCMA = list(
      description = "Baseline serum soluble B-cell maturation antigen (sBCMA) concentration",
      units = "ng/mL",
      type = "continuous",
      reference_category = NULL,
      notes = "Reported in ug/L (= ng/mL). PK driver: power exponents +0.113 on CL, +0.0401 on V1 and +0.160 on Imax (File S2 THETA12, THETA15, THETA120). KVA model: power exponent -0.200 on the upward-transition slope GNu (Table S6 SBCMABL_TVGNu; File S2 THETA28 = -0.2003). Reference 50 for all terms (File S2 SBCMAREF = 50).",
      source_name = "SBCMABL"
    ),
    BMI = list(
      description = "Baseline body mass index",
      units = "kg/m^2",
      type = "continuous",
      reference_category = NULL,
      notes = "PK driver. Power exponent -0.459 on V1; reference 27 kg/m^2 (File S2 THETA14).",
      source_name = "IBMIBL"
    ),
    RACE_ASIAN = list(
      description = "Indicator for Asian race",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (non-Asian)",
      notes = "PK driver. Multiplicative factor 0.912 on CL (File S2 THETA116, applied when the code's FDARACEN = 1). Mutually exclusive with RACE_BLACK.",
      source_name = "FDARACEN"
    ),
    RACE_BLACK = list(
      description = "Indicator for Black / African American race",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (non-Black)",
      notes = "PK driver. Multiplicative factor 0.861 on CL (File S2 THETA117, applied when the code's FDARACEN = 2). Mutually exclusive with RACE_ASIAN.",
      source_name = "FDARACEN"
    ),
    COMBO_BELAMAF = list(
      description = "Belantamab mafodotin combination therapy indicator",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (belantamab mafodotin monotherapy)",
      notes = "PK driver. Multiplicative factor 1.44 on Imax of the time-varying clearance (File S2 THETA118, applied when the code's COMBO >= 1). Also multiplies the KVA upward-transition slope GNu by 1.354 (Table S6 D678_GNu; File S2 THETA32), an effect File S2 applies to the combination studies DREAMM-6, -7 and -8, i.e. exactly the COMBO_BELAMAF = 1 patients.",
      source_name = "COMBO"
    ),
    COMBO_BOR_DEX = list(
      description = "Bortezomib plus dexamethasone (Vd) combination-therapy indicator",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (belantamab mafodotin monotherapy or another backbone)",
      notes = paste(
        "BVd (DREAMM-6 Arm B, DREAMM-7). With COMBO_POM_DEX it switches on",
        "the Vd factors 0.252 on K10, 1.32 on the upward exponent GMu and",
        "1.02 on the downward slope GNd (Table S6 BOR_K10, BOR_GMu, BOR_GNd;",
        "File S2 THETA36, THETA40, THETA41, applied when COMBO == 1 or",
        "DREAMM == 8). Mutually exclusive with COMBO_LEN_DEX and",
        "COMBO_POM_DEX.",
        sep = " "
      ),
      source_name = "COMBO"
    ),
    COMBO_LEN_DEX = list(
      description = "Lenalidomide plus dexamethasone (Rd) combination-therapy indicator",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (belantamab mafodotin monotherapy or another backbone)",
      notes = paste(
        "BRd (DREAMM-6 Arm A). Rd factors 0.624 on K21 and 3.38 on the",
        "upward exponent GMu (Table S6 LEN_K21, LEN_GMu; File S2 THETA44,",
        "THETA47, applied when COMBO == 2).",
        sep = " "
      ),
      source_name = "COMBO"
    ),
    COMBO_POM_DEX = list(
      description = "Pomalidomide plus dexamethasone (Pd) combination-therapy indicator",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (belantamab mafodotin monotherapy or another backbone)",
      notes = paste(
        "BPd (DREAMM-8). The Pd effects were set equal to the Vd effects",
        "(Results), so COMBO_POM_DEX = 1 applies the same factors as",
        "COMBO_BOR_DEX = 1 (File S2 applies them when DREAMM == 8).",
        sep = " "
      ),
      source_name = "COMBO"
    ),
    STUDY_DREAMM6 = list(
      description = "DREAMM-6 study indicator",
      units = "(binary)",
      type = "binary",
      reference_category = "0 (any other study)",
      notes = paste(
        "DREAMM-6 (NCT03544281), Arms A (BRd) and B (BVd). Adds a second",
        "power-function drug effect, 0.0780 * (C / 3.357)^0.369, to the",
        "grade 1 to 2 transition rate (Table S6 D6 GNu12, D6_GMu12; File S2",
        "THETA50, THETA51, applied when DREAMM == 6).",
        sep = " "
      ),
      source_name = "DREAMM"
    )
  )

  covariatesDataExcluded <- list(
    DRY_EYE = list(
      description = "History of dry eye per screening questionnaire",
      units = "(binary)",
      type = "binary",
      notes = "Screened in the KVA covariate analysis (Methods S1) but not retained; 14% of the analysis population (Table S5)."
    )
  )

  population <- list(
    species = "human",
    n_subjects = 959L,
    n_studies = 5L,
    age_range = "32-89 years",
    age_median = "66 years",
    weight_range = "37.0-170 kg",
    weight_median = "75.2 kg",
    sex_female_pct = 42,
    disease_state = "Relapsed/refractory multiple myeloma with at least one graded ophthalmic exam finding managed by the KVA scale (or retrospectively KVA-graded CTCAE findings).",
    dose_range = paste(
      "Belantamab mafodotin IV 1.25 to 3.4 mg/kg; initial dose 2.5 mg/kg in",
      "78% and 3.4 mg/kg in 14% (Table S5). Monotherapy (DREAMM-2,",
      "DREAMM-3) or with Vd (DREAMM-6 Arm B, DREAMM-7), Rd (DREAMM-6 Arm A)",
      "or Pd (DREAMM-8).",
      sep = " "
    ),
    biomarker_summary = paste(
      "Median (range) at baseline (Table 1): albumin 40.0 (19.0-52.3) g/L;",
      "sBCMA 49.7 (0.975-2026) ug/L; IgG 13.6 (0.350-106) g/L.",
      sep = " "
    ),
    notes = paste(
      "15,374 KVA observations from 959 patients: DREAMM-2 218, DREAMM-3",
      "203, DREAMM-6 152, DREAMM-7 238, DREAMM-8 148 (Table S2). Observed",
      "grades: 0 17%, 1 15%, 2 36%, 3 30%, 4 2%. A grade of 0 was imputed",
      "in the absence of a finding. Table 1 sex counts (404 female, 561",
      "male) and Table S5 sum to 965.",
      sep = " "
    )
  )

  ini({
    # ------------------------------------------------------------------
    # Belantamab mafodotin PK driver: Papathanasiou 2025 popPK model,
    # values as printed in the Carreno 2026 mrgsolve code (File S2,
    # $PARAM block, THETA1-THETA15 and THETA116-THETA121). The KVA model
    # was fitted to individual PK predictions from this model (Methods).
    # ------------------------------------------------------------------
    lcl <- log(0.925475); label("Clearance at time zero for the reference patient (L/day)") # File S2 THETA1 = 0.925475 (TVCL)
    lvc <- log(4.21296); label("Central volume of distribution V1 for the reference patient (L)") # File S2 THETA2 = 4.21296 (TVV1)
    lq <- log(0.710541); label("Intercompartmental clearance Q for the reference patient (L/day)") # File S2 THETA3 = 0.710541 (TVQ)
    lvp <- log(6.6294); label("Peripheral volume of distribution V2 for the reference patient (L)") # File S2 THETA4 = 6.6294 (TVV2)
    cl_time_max <- -0.402758; label("Maximal log-fold change in clearance over time, Imax, monotherapy reference (unitless)") # File S2 THETA5 = -0.402758 (TVIMAX)
    lcl_t50 <- log(66.3585); label("Time of half-maximal change in clearance, TI50 (day)") # File S2 THETA6 = 66.3585 (TVTI50)
    lcl_time_hill <- log(2.86905); label("Hill exponent of time on clearance, gamma (log unitless)") # File S2 THETA7 = 2.86905 (TVGAMMA)

    e_wt_vc_vp <- 0.928527; label("Power exponent of WT on V1 and V2 (unitless)") # File S2 THETA8 = 0.928527 (WTBLonV)
    e_wt_cl_q <- 0.54204; label("Power exponent of WT on CL and Q (unitless)") # File S2 THETA9 = 0.54204 (WTBLonCL)
    e_alb_cl <- -0.698039; label("Power exponent of ALB on CL (unitless)") # File S2 THETA10 = -0.698039 (ALBBLonCL)
    e_alb_vc <- -0.301545; label("Power exponent of ALB on V1 (unitless)") # File S2 THETA11 = -0.301545 (ALBBLonV1)
    e_sbcma_cl <- 0.112764; label("Power exponent of SBCMA on CL (unitless)") # File S2 THETA12 = 0.112764 (SBCMABLonCL)
    e_igg_cl <- 0.169878; label("Power exponent of IGG on CL (unitless)") # File S2 THETA13 = 0.169878 (IGGBLonCL)
    e_bmi_vc <- -0.45933; label("Power exponent of BMI on V1 (unitless)") # File S2 THETA14 = -0.45933 (V1IBMIBL1)
    e_sbcma_vc <- 0.0400974; label("Power exponent of SBCMA on V1 (unitless)") # File S2 THETA15 = 0.0400974 (V1SBCMABL1)
    e_race_asian_cl <- 0.912487; label("Multiplicative factor on CL for Asian race (unitless)") # File S2 THETA116 = 0.912487 (CLFDARACEN1)
    e_race_black_cl <- 0.861015; label("Multiplicative factor on CL for Black race (unitless)") # File S2 THETA117 = 0.861015 (CLFDARACEN2)
    e_combo_imax <- 1.44166; label("Multiplicative factor on Imax for combination therapy (unitless)") # File S2 THETA118 = 1.44166 (IMAXCOMBO1)
    e_igg_imax <- 0.191848; label("Power exponent of IGG on Imax (unitless)") # File S2 THETA119 = 0.191848 (IMAXIGGBL1)
    e_sbcma_imax <- 0.15972; label("Power exponent of SBCMA on Imax (unitless)") # File S2 THETA120 = 0.15972 (IMAXSBCMABL1)
    e_alb_vp <- 0.566902; label("Power exponent of ALB on V2 (unitless)") # File S2 THETA121 = 0.566902 (V2ALBBL1)
    # ------------------------------------------------------------------
    # KVA grade CTMM (Table S6; 4-significant-figure values from Table S7
    # 'Monotherapy' and File S2 $PARAM). Drug-independent rate constants
    # are first order; K01, K12, K23 and K02 are 0 (Table S6 'K01 0 FIX';
    # File S2 THETA17, THETA19, THETA21, THETA23 = 0) and are therefore
    # omitted; K20 = K21 (Results).
    # ------------------------------------------------------------------
    llambda10 <- log(0.02806); label("Drug-independent grade 1 to 0 rate constant K10, monotherapy (1/day)") # Table S6: K10 = 0.0281 1/d; Table S7 monotherapy 0.02806; File S2 THETA18
    llambda21 <- log(0.009361); label("Drug-independent grade 2 to 1 (and 2 to 0) rate constant K21, monotherapy (1/day)") # Table S6: K21 = 0.00936 1/d; Table S7 monotherapy 0.009361; File S2 THETA20
    llambda32 <- log(0.03338); label("Drug-independent grade 3/4 to 2 rate constant K32 (1/day)") # Table S6: K32 = 0.0334 1/d; Table S7 0.03338; File S2 THETA22
    lgnu <- log(0.02145); label("Slope of the upward drug-effect power function GNu, monotherapy (1/day)") # Table S6: GNu = 0.0214 1/d; Table S7 monotherapy 0.02145; File S2 THETA24
    gmu <- 0.1549; label("Exponent of the upward drug-effect power function GMu, monotherapy (unitless)") # Table S6: GMu = 0.155; Table S7 monotherapy 0.1549; File S2 THETA25
    lgnd <- log(3.908); label("Slope of the downward drug-effect function GNd, monotherapy (unitless)") # Table S6: GNd = 3.91; Table S7 monotherapy 3.908; File S2 THETA26
    gmd <- 0.6998; label("Exponent of the downward drug-effect power function GMd (unitless)") # Table S6: GMd = 0.700; Table S7 0.6998; File S2 THETA27
    cref_kva <- fixed(3.357); label("Normalising belantamab mafodotin concentration of the KVA power functions (ug/mL)") # File S2: medDRIVR = 3.357, a constant of the code, not an estimate

    e_sbcma_gnu <- -0.2003; label("Power exponent of SBCMA / 50 on GNu (unitless)") # Table S6: SBCMABL_TVGNu = -0.200; File S2 THETA28 = -0.2003
    e_combo_gnu <- 1.354; label("Multiplicative factor on GNu for combination therapy (unitless)") # Table S6: D678_GNu = 1.35; File S2 THETA32 = 1.354
    e_bor_lambda10 <- 0.2517; label("Multiplicative factor on K10 for Vd or Pd (unitless)") # Table S6: BOR_K10 = 0.252; File S2 THETA36 = 0.2517
    e_bor_gmu <- 1.325; label("Multiplicative factor on GMu for Vd or Pd (unitless)") # Table S6: BOR_GMu = 1.32; File S2 THETA40 = 1.325
    e_bor_gnd <- 1.022; label("Multiplicative factor on GNd for Vd or Pd (unitless)") # Table S6: BOR_GNd = 1.02; File S2 THETA41 = 1.022
    e_len_lambda21 <- 0.6236; label("Multiplicative factor on K21 for Rd (unitless)") # Table S6: LEN_K21 = 0.624; File S2 THETA44 = 0.6236
    e_len_gmu <- 3.376; label("Multiplicative factor on GMu for Rd (unitless)") # Table S6: LEN_GMu = 3.38; File S2 THETA47 = 3.376
    gnu12_dreamm6 <- 0.07795; label("Slope of the additional DREAMM-6 grade 1 to 2 drug effect (1/day)") # Table S6: D6 GNu12 = 0.0780; File S2 THETA50 = 0.07795
    gmu12_dreamm6 <- 0.3686; label("Exponent of the additional DREAMM-6 grade 1 to 2 drug effect (unitless)") # Table S6: D6_GMu12 = 0.369; File S2 THETA51 = 0.3686

    # ------------------------------------------------------------------
    # Inter-individual variability. PK etas are not reported by Carreno
    # 2026 (the framework used individual post hoc PK estimates); they
    # are carried from the Papathanasiou 2025 model, as packaged in
    # modellib('Papathanasiou_2025_belantamab').
    # ------------------------------------------------------------------
    etalcl + etalvc ~ c(
      0.06593,
      0.0328, 0.03922
    ) # carried from Papathanasiou_2025_belantamab (Papathanasiou 2025 Table 2: CL CV 26.1%, Vc CV 20.0%, covariance 0.0328)
    etalq ~ 0.03546 # carried from Papathanasiou_2025_belantamab (Papathanasiou 2025 Table 2: Q CV 19.0%)
    etalvp ~ 0.08945 # carried from Papathanasiou_2025_belantamab (Papathanasiou 2025 Table 2: Vp CV 30.6%)
    etacl_time_max ~ 0.01366 # carried from Papathanasiou_2025_belantamab (Papathanasiou 2025 Table 2: Imax CV 29.0%, additive)
    etalcl_t50 ~ 0.39236 # carried from Papathanasiou_2025_belantamab (Papathanasiou 2025 Table 2: TI50 CV 69.3%)
    etallambda21 ~ 1.01 # Table S6: omega2 K21 = 1.01
    etallambda32 ~ 1.08 # Table S6: omega2 K32 = 1.08
    etalgnu ~ 0.584 # Table S6: omega2 GNu = 0.584

    propSd <- 0.2516; label("PK proportional residual error (fraction)") # carried from Papathanasiou_2025_belantamab (Papathanasiou 2025 Table 2: sqrt(0.0633))
  })

  model({
    # 1. PK driver (File S2 $PK).
    cl_time_max_i <- cl_time_max * e_combo_imax^COMBO_BELAMAF *
      (IGG / 15)^e_igg_imax * (SBCMA / 50)^e_sbcma_imax + etacl_time_max
    cl_t50_i <- exp(lcl_t50 + etalcl_t50)
    cl_time_hill <- exp(lcl_time_hill)
    cl_base <- exp(lcl + etalcl) * (WT / 75)^e_wt_cl_q * (ALB / 40)^e_alb_cl *
      (SBCMA / 50)^e_sbcma_cl * (IGG / 15)^e_igg_cl *
      e_race_asian_cl^RACE_ASIAN * e_race_black_cl^RACE_BLACK
    cl <- cl_base * exp(cl_time_max_i * t^cl_time_hill / (cl_t50_i^cl_time_hill + t^cl_time_hill))
    vc <- exp(lvc + etalvc) * (WT / 75)^e_wt_vc_vp * (ALB / 40)^e_alb_vc *
      (BMI / 27)^e_bmi_vc * (SBCMA / 50)^e_sbcma_vc
    q <- exp(lq + etalq) * (WT / 75)^e_wt_cl_q
    vp <- exp(lvp + etalvp) * (WT / 75)^e_wt_vc_vp * (ALB / 40)^e_alb_vp

    kel <- cl / vc
    k12 <- q / vc
    k21 <- q / vp
    # 2. KVA transition parameters (File S2 CORNEAL TOXICITY MODEL block).
    #    The Vd factors also apply to Pd; the backbones are mutually
    #    exclusive, so vd_or_pd is 0 or 1.
    vd_or_pd <- COMBO_BOR_DEX + COMBO_POM_DEX
    lambda10 <- exp(llambda10) * e_bor_lambda10^vd_or_pd
    lambda21 <- exp(llambda21 + etallambda21) * e_len_lambda21^COMBO_LEN_DEX
    lambda20 <- lambda21
    lambda32 <- exp(llambda32 + etallambda32)
    gnu <- exp(lgnu + etalgnu) * e_combo_gnu^COMBO_BELAMAF * (SBCMA / 50)^e_sbcma_gnu
    gmu_i <- gmu * e_bor_gmu^vd_or_pd * e_len_gmu^COMBO_LEN_DEX
    gnd <- exp(lgnd) * e_bor_gnd^vd_or_pd
    gnu12_d6 <- gnu12_dreamm6 * STUDY_DREAMM6

    # 3. ODEs. Dose in mg and volume in L give Cc in mg/L = ug/mL.
    d/dt(central) <- -kel * central - k12 * central + k21 * peripheral1
    d/dt(peripheral1) <- k12 * central - k21 * peripheral1

    Cc <- central / vc

    # Drug effects (File S2 $DES): power functions of Cc / 3.357. Upward
    # rates are the drug effect alone (the drug-independent upward rates
    # are 0); downward rates are K * GNd / (1 + GNd * (Cc / 3.357)^GMd), so
    # they fall as concentration rises and equal K * GNd without drug.
    cnorm <- Cc / cref_kva
    if (cnorm < 0) cnorm <- 0
    eff_up <- gnu * cnorm^gmu_i
    eff_up12 <- eff_up + gnu12_d6 * cnorm^gmu12_dreamm6
    eff_down <- gnd * cnorm^gmd

    r01 <- eff_up
    r02 <- eff_up
    r12 <- eff_up12
    r23 <- eff_up
    r10 <- lambda10 * gnd / (1 + eff_down)
    r20 <- lambda20 * gnd / (1 + eff_down)
    r21 <- lambda21 * gnd / (1 + eff_down)
    r32 <- lambda32 * gnd / (1 + eff_down)

    d/dt(s_kva0) <- -(r01 + r02) * s_kva0 + r10 * s_kva1 + r20 * s_kva2
    d/dt(s_kva1) <- r01 * s_kva0 - (r10 + r12) * s_kva1 + r21 * s_kva2
    d/dt(s_kva2) <- r02 * s_kva0 + r12 * s_kva1 - (r20 + r21 + r23) * s_kva2 + r32 * s_kva34
    d/dt(s_kva34) <- r23 * s_kva2 - r32 * s_kva34

    # 4. Every patient starts at grade 0 (no ophthalmic finding).
    s_kva0(0) <- 1

    # 5. Observations. KVA grade is an ordinal endpoint: category 1 = grade
    #    0, 2 = grade 1, 3 = grade 2, 4 = grade 3 or 4.
    p_total <- s_kva0 + s_kva1 + s_kva2 + s_kva34
    p_kva0 <- s_kva0 / p_total
    p_kva1 <- s_kva1 / p_total
    p_kva2 <- s_kva2 / p_total
    p_kva34 <- s_kva34 / p_total

    Cc ~ prop(propSd)
    kva_grade ~ c(p_kva0, p_kva1, p_kva2)
  })
}
